RCT | Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer.

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) – Journal of Clinical Oncology

Commentary: Selumetinib Does Not Improve CR Rate in Differentiated Thyroid Cancer – Cancer Therapy Adviser

Commentary on Twitter

❎ ASTRA trial: Radioactive iodine ± selumetinib doesn't improve remission rates for high-risk #thyroidcancer
✅ Postoperative pathologic risk stratification identified pts at risk of primary treatment failurehttps://t.co/kvakaMXtDh#JCO #thycsm @MSKCancerCenter pic.twitter.com/mvQwgzIjWh

— Journal of Clinical Oncology (@JCO_ASCO) March 16, 2022